Please login to the form below

Vyndaqel

This page shows the latest Vyndaqel news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

EU approval will help drug achieve blockbuster status. Pfizer’s resurgent rare disease drug Vyndaqel has had its uses extended by the EMA, becoming the first drug in the EU for ... Prior to Vyndaqel, treatment options for patients with ATTR

Latest news

Vyndaqel a bright spot as Pfizer comes under pressure

The big boost for Pfizer came from Vyndaqel/Vyndamax (tafamidis) for rare disease transthyretin-mediated amyloidosis (ATTR), which swelled to $213m in the fourth quarter from just $39m a year earlier ... As of the end of 2019 more than 9, 000 ATTR
Alnylam gains key NICE approval for Onpattro

decision. The two rivals also face competition from Pfizer’s Vyndaqel (tafadamis). It has been available in Europe for a number of years as a polyneuropathy treatment, but recently gained US ... The company also highlighted the fact that around a third
Pfizer buys dwarfism drug company Therachon for $810m

The deal adds to Pfizer’s rare disease portfolio, which just chalked up a major success with the approval of tafamidis products Vyndaqel and Vyndamax for transthyretin amyloid cardiomyopathy (ATTR-CM)
Speedy approval for Pfizer's Onpattro rival

Both Vyndamax and Vyndaqel are expected to reduce cardiovascular mortality by 30% and cut cardiovascular related hospitalisation by 32%, strong claims which will help fuel their uptake. ... Vyndaqel has been priced at $225, 000 per year, half the price
Alnylam gets EU nod for Onpattro amid pricing backlash

s Vyndaqel (tafamidis) has been registered in Europe since 2011 and costs in the region of $13, 000 per month. ... Neither Tegsedi or Vyndaqel are approved yet in the US, although Akcea and Ionis are due to hear from the FDA in October and Pfizer has

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma leaders to watch in 2020

to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance (palbociclib) and arthritis drug Xeljanz (tofacitinib), among others. ... Standing in its way is a similarly priced antisense rival from
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

produced impressive data for its Vyndaqel (tafamidis). ... Vyndaqel has been available in Europe since 2011 for Transthyretin (TTR) amyloid polyneuropathy, but isn’t yet approved in the US.
Tough times for pharma in Portugal

spondylitis. For instance, the Portuguese Association of Amyloidosis (APP) is petitioning parliament for access to Pfyzer's Vyndaqel (tafamidis).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Improve clinical trials through patient journey mapping: Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...